Interestingly, even some tumours with intact BRCA1/2 may exhibit sensitivity to PARPi, such as glioblastomas (GBM), where treatment with olaparib (a PARP inhibitor) showed promising results in pre-clinical21, 22 and phase I clinical studies (https://clinicaltrials.gov). This evidence concerns the gene PARP1 and glioblastoma.